FDA Grants Breakthrough Therapy Designation to NVG-291 for Chronic Spinal Cord Injury
NGEN sits 19% above its 52-week low of $1.28.
Summary
The FDA granted Breakthrough Therapy designation to NVG-291 for chronic traumatic cervical motor-incomplete spinal cord injury, a first for the program and a meaningful regulatory de-risking event for a micro-cap biotech. The designation rests on Phase 1b/2a CONNECT SCI data showing substantial gains in a clinically significant hand-function endpoint, supported by patient-reported improvement and no serious adverse events. It brings eligibility for Priority Review, rolling NDA submission, and closer FDA guidance, which can shorten the path to approval. The Phase 3 RESTORE registrational study is enrolling roughly 150 participants across the US and Canada with hand function as the primary endpoint. This lands while the company is still working through restated FY2024/FY2025 and Q2 2026 financials and a disclosed material weakness in internal controls, so the regulatory win is the clearest positive news in months. Watch RESTORE enrollment progress and any FDA interaction timelines disclosed next.
At the time of this announcement, NGEN was trading at $1.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $145.3M. The 52-week trading range was $1.28 to $6.30. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.